

ANDREW M. CUOMO Governor **HOWARD A. ZUCKER, M.D., J.D.**Acting Commissioner

SALLY DRESLIN, M.S., R.N. Executive Deputy Commissioner

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective 05/26/2016, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- Imitrex Kit will be added to the program.
- Abilify and Cymbalta will be <u>removed</u> from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated): 05/12/2016

Adderall XR	Focalin XR 5mg, 10mg, 15mg,20mg,30mg,40mg	Renvela
Aggrenox	Gabitril 2mg, 4mg	Soriatane
Aldara	Gleevec	Tegretol suspension
Alphagan P 0.15%	Hepsera	Tegretol XR
Astepro	Imitrex Kit	Tobradex suspension
Baraclude	Kapvay	Tricor
Catapres-TTS	Mepron	Trilipix
Cellcept suspension	Myfortic	Trizivir
Combivir	Nasonex	Valcyte
Copaxone 20ml SQ	Niaspan	Voltaren Gel
Diastat	Patanase	Xeloda
Epivir HBV tablet	Protopic	Xenazine
Exelon Patch	Pulmicort Respules	

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.